Fulgent Genetics (FLGT)

Executive Summary

Fulgent Genetics is a leading clinical diagnostics company with a robust portfolio of over 18,000 single-gene tests and 900+ rare disease panels, operating six CLIA- and CAP-accredited labs. The company leverages proprietary next-generation sequencing (NGS) to deliver comprehensive genetic testing services. Recently, Fulgent has expanded beyond diagnostics by integrating a novel nanoencapsulation therapeutic platform, aiming to become a fully integrated precision medicine company. This strategic pivot positions Fulgent to address both diagnostic and therapeutic needs in rare diseases, potentially unlocking significant value. However, the therapeutic platform is still early-stage, and the company faces competition from larger genomics players. Financially, Fulgent has a market cap of ~$431M and a cash position that supports R&D investments. The core diagnostic business continues to generate recurring revenue, though growth has moderated post-pandemic. Key near-term drivers include commercial expansion of the test menu and progress in the therapeutic pipeline.

Upcoming Catalysts (preview)

• Q3 2026Launch of expanded rare disease panels and liquid biopsy tests85% success
• Q4 2026Preclinical data or IND filing for nanoencapsulation platform40% success
• Q3 2026Q2 2026 earnings report demonstrating diagnostic revenue stability90% success